- Home
- CANF vs ECPG Comparison
CANF vs ECPG Comparison
Compare CANF & ECPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ECPG
- Stock Information
- Founded
- CANF 1994
- ECPG 1998
- Country
- CANF Israel
- ECPG United States
- Employees
- CANF N/A
- ECPG N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ECPG Finance Companies
- Sector
- CANF Health Care
- ECPG Finance
- Exchange
- CANF Nasdaq
- ECPG Nasdaq
- Market Cap
- CANF 7.9M
- ECPG N/A
- IPO Year
- CANF N/A
- ECPG 1999
- Fundamental
- Price
- CANF $1.13
- ECPG $34.38
- Analyst Decision
- CANF Strong Buy
- ECPG Strong Buy
- Analyst Count
- CANF 2
- ECPG 3
- Target Price
- CANF $14.00
- ECPG $62.67
- AVG Volume (30 Days)
- CANF 423.1K
- ECPG 339.8K
- Earning Date
- CANF 05-06-2025
- ECPG 05-07-2025
- Dividend Yield
- CANF N/A
- ECPG N/A
- EPS Growth
- CANF N/A
- ECPG N/A
- EPS
- CANF N/A
- ECPG N/A
- Revenue
- CANF $674,000.00
- ECPG $1,316,361,000.00
- Revenue This Year
- CANF $461.72
- ECPG $21.62
- Revenue Next Year
- CANF N/A
- ECPG $10.12
- P/E Ratio
- CANF N/A
- ECPG N/A
- Revenue Growth
- CANF N/A
- ECPG 7.66
- 52 Week Low
- CANF $1.22
- ECPG $26.45
- 52 Week High
- CANF $4.69
- ECPG $51.77
- Technical
- Relative Strength Index (RSI)
- CANF 35.40
- ECPG 54.30
- Support Level
- CANF $1.14
- ECPG $28.93
- Resistance Level
- CANF $1.27
- ECPG $34.97
- Average True Range (ATR)
- CANF 0.12
- ECPG 2.20
- MACD
- CANF -0.02
- ECPG 0.84
- Stochastic Oscillator
- CANF 0.00
- ECPG 93.08
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).